Výsledky vyhledávání

CLO19-024: Risk of Atrial Fibrillation and Pulmonary Toxicities in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated With Ibrutinib

Autor: Khaing Khaing Htwe, Anita Sultan, Tun W. Naing, Upama Sharma, Kyaw Zin Thein, Myo H. Zaw, Wai P. Thi, Sriman Swarup, Nimesh Adhikari, Nay N. Yee

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:CLO19-024

Background: Bruton’s tyrosine kinase (BTK), a kinase downstream of the B-cell receptor, involves in the B cell survival and proliferation and has become an attractive therapeutic target. Ibrutinib is an oral potent, covalent inhibitor of BTK and he

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a87cb3ee2c2da6df6d1ad9a7b2175b8a
https://doi.org/10.6004/jnccn.2018.7158

Zobrazit plný text záznamu

CLO19-025: Treatment Discontinuation Due to Adverse Events and the Risk of Gastrointestinal Toxicities in Patients With Hematologic Malignancies Treated With Ibrutinib

Autor: Sriman Swarup, Nay N. Yee, Kyaw Zin Thein, Myo H. Zaw, Wai Lin Thein, Meily Arevalo, Anita Sultan, Nusrat Jahan, Myet Mon Mon Zin

Publikováno v: Journal of the National Comprehensive Cancer Network. 17:CLO19-025

Background: Ibrutinib targets Bruton’s tyrosine kinase, a kinase involved in signaling of B-cell and chemokine receptors, which are implicated in the pathogenesis of hematologic malignancies. Ibrutinib has been shown to improve survival in hematolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b71d8e4265f6eee60ef3fb74a06d8ae5
https://doi.org/10.6004/jnccn.2018.7171

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání